Lee Hye Won, Chon Young Eun, Kim Seung Up, Kim Beom Kyung, Park Jun Yong, Kim Do Young, Ahn Sang Hoon, Jung Kyu Sik, Park Young Nyun, Han Kwang-Hyub
Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
Institute of Gastroenterology, Yonsei University College of Medicine, Seoul, Korea.
Gut Liver. 2016 May 23;10(3):429-36. doi: 10.5009/gnl15021.
BACKGROUND/AIMS: Few studies have investigated prognostic factors for the development of liver-related events (LREs) in patients with chronic hepatitis C (CHC) who achieve sustained virological response (SVR).
We analyzed 190 patients with CHC who achieved SVR after treatment with pegylated interferon (peg-IFN) plus ribavirin. LREs were defined as any complications related to cirrhosis, hepatocellular carcinoma (HCC), or liver-related mortality.
The mean age was 54.1 years, and 84 of the patients (44.2%) were male. The mean liver stiffness (LS) value at SVR was 7.1±5.4 kPa. During the follow-up period (median, 43.0 months), LREs occurred in 10 patients (5.3%; HCC in eight patients, ascites in one patient, and liver-related mortality in one patient). By multivariate Cox regression analysis, age, α-fetoprotein level, and LS value were independent predictors for LRE development (all p<0.05). Patients with LS values ≥7.0 kPa had a greater risk (hazard ratio, 9.472; 95% confidence interval, 1.018 to 88.126; p=0.048) for LRE development compared to those with LS values <7.0 kPa.
The LS value at SVR is useful for predicting LRE development in CHC patients who achieve SVR after treatment with peg-IFN plus ribavirin. Thus, LRE surveillance strategies might be optimized according to the LS values at SVR, even with complete viral eradication.
背景/目的:很少有研究调查过获得持续病毒学应答(SVR)的慢性丙型肝炎(CHC)患者发生肝脏相关事件(LRE)的预后因素。
我们分析了190例接受聚乙二醇干扰素(peg-IFN)联合利巴韦林治疗后获得SVR的CHC患者。LRE被定义为与肝硬化、肝细胞癌(HCC)或肝脏相关死亡相关的任何并发症。
患者平均年龄为54.1岁,其中84例(44.2%)为男性。SVR时的平均肝脏硬度(LS)值为7.1±5.4 kPa。在随访期(中位数为43.0个月)内,10例患者(5.3%)发生了LRE(8例为HCC,1例为腹水,1例为肝脏相关死亡)。通过多因素Cox回归分析,年龄、甲胎蛋白水平和LS值是LRE发生的独立预测因素(均p<0.05)。与LS值<7.0 kPa的患者相比,LS值≥7.0 kPa的患者发生LRE的风险更高(风险比为9.472;95%置信区间为1.018至88.126;p=0.048)。
SVR时的LS值有助于预测接受peg-IFN联合利巴韦林治疗后获得SVR的CHC患者发生LRE。因此,即使病毒已被完全清除,也可根据SVR时的LS值优化LRE监测策略。